LIVANOVA PLC
NASDAQ: LIVN (LivaNova PLC)
Last update: 2 days ago, 4:16PM61.96
-0.92 (-1.46%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bullish | Bearish |
| Medical Devices (Global) | Bullish | Bearish | |
| Stock | LivaNova PLC | Bullish | Bullish |
Analyst Consensus
2 Buy, 2 Hold
Avg. Price @ Call: 61.09
|
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dme Capital Management, Lp | 31 Mar 2024 | 1,332,804 |
| Greenlight Capital Inc | 31 Dec 2023 | 1,229,316 |
| 52 Weeks Range |
42.75 - 64.48
|
|
| Price Target Range | ||
| High | 80.00 (Mizuho, 29.12%) | Buy |
| Median | 69.00 (11.36%) | |
| Low | 61.00 (Barclays, -1.55%) | Hold |
| Average | 69.75 (12.57%) | |
| Total | 2 Buy, 2 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 02 May 2024 | 66.00 (6.52%) | Hold | 62.92 |
| 22 Feb 2024 | 62.00 (0.06%) | Hold | 56.24 | |
| Mizuho | 02 May 2024 | 80.00 (29.12%) | Buy | 62.92 |
| 27 Mar 2024 | 75.00 (21.05%) | Buy | 55.87 | |
| Needham | 01 May 2024 | 72.00 (16.20%) | Buy | 62.62 |
| 20 Mar 2024 | 72.00 (16.20%) | Buy | 56.63 | |
| Barclays | 27 Feb 2024 | 61.00 (-1.55%) | Hold | 55.90 |
| 26 Feb 2024 | 61.00 (-1.55%) | Hold | 55.97 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2024 | Announcement | LivaNova Reports First-Quarter 2024 Results |
| 30 Apr 2024 | Announcement | LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer |
| 25 Apr 2024 | Announcement | LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident |
| 21 Mar 2024 | Announcement | LivaNova to Announce First-Quarter 2024 Results |
| 20 Mar 2024 | Announcement | LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea |
| 05 Mar 2024 | Announcement | LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029 |
| 04 Mar 2024 | Announcement | LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes |
| 04 Mar 2024 | Announcement | LivaNova to Present at the Barclays Global Healthcare Conference |
| 21 Feb 2024 | Announcement | LivaNova Reports Fourth-Quarter and Full-Year 2023 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |